MLICM
HZNP

Metropolitan Life Insurance Company (MetLife)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,256
Closed -$674K – 2819
2021
Q4 		$674K Sell
6,256
-11
-0.2% -$1.2K 0.01% 1228
2021
Q3 		$686K Buy
+6,267
New +$651K 0.01% 1229
2021
Q2 		– Sell
-13,420
Closed -$1.24M – 2965
2021
Q1 		$1.24M Sell
13,420
-580
-4% -$48.9K 0.02% 795
2020
Q4 		$1.02M Sell
14,000
-275
-2% -$20.4K 0.02% 868
2020
Q3 		$1.11M Buy
14,275
+486
+4% +$33.4K 0.02% 682
2020
Q2 		$766K Buy
13,789
+8,301
+151% +$355K 0.01% 904
2020
Q1 		$163K Sell
5,488
-48
-0.9% -$1.62K ﹤0.01% 1713
2019
Q4 		$200K Buy
5,536
+56
+1% +$1.72K ﹤0.01% 1926
2019
Q3 		$149K Sell
5,480
-51,225
-90% -$1.32M ﹤0.01% 2080
2019
Q2 		$1.36M Hold
56,705
– – 0.02% 714
2019
Q1 		$1.5M Buy
56,705
+1,749
+3% +$41.4K 0.03% 640
2018
Q4 		$1.07M Buy
54,956
+1,236
+2% +$24.2K 0.02% 770
2018
Q3 		$1.05M Buy
+53,720
New +$1.02M 0.02% 905
2015
Q1 		– Sell
-49,867
Closed -$643K – 2544
2014
Q4 		$643K Buy
+49,867
New +$624K ﹤0.01% 1594
2014
Q3 		– Sell
-46,364
Closed -$733K – 2765
2014
Q2 		$733K Hold
46,364
– – 0.01% 1559
2014
Q1 		$701K Hold
46,364
– – ﹤0.01% 1582
2013
Q4 		$353K Buy
46,364
+2,807
+6% +$15.1K ﹤0.01% 2062
2013
Q3 		$147K Buy
+43,557
New +$115K ﹤0.01% 2628

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HZNP Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 6,256 shares — an estimated $674K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HZNP in Q3 2013 and held it in 18 quarters. The position peaked at $1.5M in Q1 2019. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,256 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $674K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 18 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.5M in Q1 2019.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.